AMORPHOUS METAXALONE AND AMORPHOUS DISPERSIONS THEREOF
The present invention provides various amorphous forms of the compound metaxalone (I), such as solid amorphous metaxalone and amorphous dispersions comprising metaxalone. The present invention further provides pharmaceutical compositions comprising these amorphous forms, and methods of their preparation. The present invention additionally provides methods of treating painful conditions (e.g., such as painful musculoskeletal conditions) comprising administering a therapeutically effective amount of any one of these amorphous forms to a subject in need thereof.
1 . Amorphous metaxalone.
2 . A pharmaceutical composition comprising amorphous metaxalone and one or more pharmaceutically acceptable excipients.
3 . The pharmaceutical composition of claim 2 , wherein said amorphous metaxalone is substantially free of crystalline metaxalone.
4 . The pharmaceutical composition of claim 2 , further comprising crystalline metaxalone.
5 . A method of preparing amorphous metaxalone, comprising steps of (i) melting metaxalone to produce a molten product; and (ii) cooling the molten product to yield amorphous metaxalone.
6 . The method according to claim 5 , wherein the step of melting comprises heating the metaxalone to a temperature of between about 100° C. to 200° C.
7 . The method according to claim 5 , wherein the step of cooling comprises cooling the molten product to a temperature of between about 25° C. to −100° C.
8 . The method according to claim 5 , wherein the step of melting comprises heating the metaxalone to a temperature of between about 120° C. to 160° C. and the step of cooling comprises cooling the molten product to a temperature of between about −50° C. to −80° C.
9 . The method according to claim 8 , wherein the step of melting comprises melting crystalline metaxalone.
10 . An amorphous dispersion comprising metaxalone and a dispersing aid.
11 . The amorphous dispersion of claim 10 , wherein the dispersing aid is HPMC and the amorphous dispersion exhibits an X-ray diffraction pattern with two broad diffuse halos having maxima expressed in angle 2-theta at about 8 degrees and about 20 degrees.
12 . The amorphous dispersion of claim 10 , wherein the dispersing aid is HPMC-phthalate and the amorphous dispersion exhibits an X-ray diffraction pattern with a broad diffuse halo having a maximum expressed in angle 2-theta at about 21 degrees.
13 . The amorphous dispersion of claim 12 , wherein metaxalone and the dispersing aid are present in about equal amounts by weight.
14 . The amorphous dispersion of claim 10 , wherein the dispersing aid is PVP and the amorphous dispersion exhibits an X-ray diffraction pattern with a broad diffuse halo having a maximum expressed in angle 2-theta at about 21 degrees.
15 . The amorphous dispersion of claim 14 , wherein the X-ray diffraction pattern includes a second weaker broad diffuse halo having a maximum expressed in angle 2-theta at about 12 degrees.
16 . A pharmaceutical composition comprising an amorphous dispersion of claim 10 and one or more pharmaceutically acceptable excipients.
17 . A method of preparing an amorphous dispersion of metaxalone comprising steps of (i) melting metaxalone and a dispersing aid to produce a molten product; and (ii) cooling the molten product to yield an amorphous dispersion.
18 . The method according to claim 17 , wherein the step of melting comprises heating the metaxalone and dispersing aid to a temperature of between about 100° C. to 200° C.
19 . The method according to claim 17 , wherein the step of cooling comprises cooling the molten product to a temperature of between about 25° C. to −100° C.
20 . The method according to claim 17 , wherein the step of melting comprises heating the metaxalone and dispersing aid to a temperature of between about 120° C. to 160° C. and the step of cooling comprises cooling the molten product to a temperature of between about −50° C. to −80° C.
21 . A method of preparing an amorphous dispersion of metaxalone comprising steps of (i) dissolving at least a portion of metaxalone and at least a portion of a dispersing aid in a common solvent, and (ii) removing the common solvent to yield an amorphous dispersion.
22 . The method according to claim 21 , wherein the step of removing the common solvent comprises removal by evaporation or removal by spray-drying.
23 . The method according to claim 22 , wherein the common solvent is methanol, ethanol, n-propanol, isopropyl alcohol (IPA), hexafluoroisopropyl alcohol (HFIPA), sec-butanol, n-butanol, acetone, methyl ethyl ketone, 3-pentanone, methyl iso-butyl ketone, ethyl acetate, propylacetate, toluene, dichloromethane (DCM), chloroform, 1,1,1-trichloroethane, tetrahydrofuran (THF), dioxane, diethyl ether, acetonitrile (ACN), or a mixture thereof.
24 . The method according to claim 22 , wherein the common solvent is acetone or dichloromethane (DCM).
25 . A method of treating a painful condition comprising administering a therapeutically effective amount of amorphous metaxalone to a patient in need thereof.
26 . A method of treating a painful condition comprising administering a therapeutically effective amount of an amorphous dispersion of metaxalone comprising metaxalone and a dispersing aid to a patient in need thereof.